JIA-HORNG KAO2021-09-042021-09-0420180929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052922205&doi=10.1016%2fj.jfma.2018.08.020&partnerID=40&md5=ae1a94a50efd09aa43ad6b06df994111https://scholars.lib.ntu.edu.tw/handle/123456789/581832[SDGs]SDG3adefovir dipivoxil; alpha2b interferon; antivirus agent; entecavir; hepatitis B antibody; hepatitis B core antigen; hepatitis B surface antigen; hepatitis B vaccine; interferon; lamivudine; nucleoside analog; nucleotide derivative; peginterferon alpha2a; telbivudine; tenofovir alafenamide; tenofovir disoproxil; antivirus agent; antiviral therapy; chronic hepatitis B; cytotoxic T lymphocyte; decompensated liver cirrhosis; disease exacerbation; human; immunoprophylaxis; infection control; liver cell; liver cirrhosis; liver disease; Short Survey; treatment outcome; chronic hepatitis B; disease management; drug effect; Hepatitis B virus; vaccination; Antiviral Agents; Disease Management; Hepatitis B virus; Hepatitis B, Chronic; Humans; Vaccinationshort survey10.1016/j.jfma.2018.08.020302011912-s2.0-85052922205